Category: Uncategorized

BioXgen’s cardiac patch goes on during surgery, works through the four-day POAF risk window, and resorbs into surrounding tissue before the patient leaves recovery.

Post-operative atrial fibrillation develops in up to 50% of open-heart surgery patients within the first four days after the procedure, doubling mortality risk, quadrupling stroke likelihood, driving a sevenfold increase in acute kidney injury, and extending hospital stays by three to seven days on average. For roughly 45% of those patients it becomes a recurring […]

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations.
Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.
Forward looking statements were included here that the Company believes to be accurate given the current information. They involve known and unknown risks, uncertainties and other important factors which
if changed may affect the outcome(s).
DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 30 East 23rd Street, 2nd Floor, NY, NY 10010, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA’s BrokerCheck.
DealMaker Securities LLC does not make investment recommendations.
DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer.
DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor’s documentation for this investment.
DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing.
DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself.
Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investorʼs submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer-related matters.
Forward looking statements were included here that the Company believes to be accurate given the current information. They involve known and unknown risks, uncertainties and other important factors which if changed may affect the outcome(s).
Past performance is not indicative of future results.

Sources

©2026 All Rights Reserved

Advertising by Potomac Growth Inc

Sources

  1. Helgadottir S, Sigurdsson MI, Ingvarsdottir IL, Arnar DO, Gudbjartsson T. Atrial fibrillation following cardiac surgery: risk analysis and long-term survival. J Cardiothorac Surg 2012;7:87. DOI: 10.1186/1749-8090-7-87.
  2. Dobrev D, Aguilar M, Heijman J, Guichard JB, Nattel S. Postoperative atrial fibrillation: mechanisms, manifestations and management. Nat Rev Cardiol 2019;16(7):417-436. DOI: 10.1038/s41569-019-0166-5.
  3. Woldendorp K, Farag J, Khadra S, Black D, Robinson B, Bannon P. Postoperative Atrial Fibrillation After Cardiac Surgery: A Meta-Analysis. Ann Thorac Surg. 2021 Dec;112(6):2084-2093. doi: 10.1016/j.athoracsur.2020.10.055. Epub 2020 Dec 16. PMID: 33340521.
  4. Taha A, Nielsen SJ, Bergfeldt L, Ahlsson A, Friberg L, Björck S, Franzén S, Jeppsson A. New-Onset Atrial Fibrillation After Coronary Artery Bypass Grafting and Long-Term Outcome: A Population-Based Nationwide Study From the SWEDEHEART Registry. J Am Heart Assoc. 2021 Jan 5;10(1):e017966. doi: 10.1161/JAHA.120.017966. Epub 2020 Nov 30. PMID: 33251914; PMCID: PMC7955471.
  5. Helgadottir S, Sigurdsson MI, Ingvarsdottir IL, Arnar DO, Gudbjartsson T. Atrial fibrillation following cardiac surgery: risk analysis and long-term survival. J Cardiothorac Surg 2012;7:87. DOI: 10.1186/1749-8090-7-87.
  6. Dobrev D, Aguilar M, Heijman J, Guichard JB, Nattel S. Postoperative atrial fibrillation: mechanisms, manifestations and management. Nat Rev Cardiol 2019;16(7):417-436. DOI: 10.1038/s41569-019-0166-5.
  7. Woldendorp K, Farag J, Khadra S, Black D, Robinson B, Bannon P. Postoperative Atrial Fibrillation After Cardiac Surgery: A Meta-Analysis. Ann Thorac Surg. 2021 Dec;112(6):2084-2093. doi: 10.1016/j.athoracsur.2020.10.055. Epub 2020 Dec 16. PMID: 33340521.
  8. Guenancia C, Pujos C, Debomy F, Malapert G, Laurent G, Bouchot O. Incidence and Predictors of New-Onset Silent Atrial Fibrillation after Coronary Artery Bypass Graft Surgery. Biomed Res Int 2015;2015:703685. DOI: 10.1155/2015/703685.
  9. Swinn T, Pezard-Snell M, Brain L, Dimitropoulos G, Dastidar A, Sammut E, Barman P. Recurrence of atrial fibrillation after cardiac surgery: long-term evidence from cardiac devices. Front Cardiovasc Med. 2025 Oct 3;12:1669461. doi: 10.3389/fcvm.2025.1669461. PMID: 41112224; PMCID: PMC12531181.
  10. Taha A, Nielsen SJ, Bergfeldt L, Ahlsson A, Friberg L, Björck S, Franzén S, Jeppsson A. New-Onset Atrial Fibrillation After Coronary Artery Bypass Grafting and Long-Term Outcome: A Population-Based Nationwide Study From the SWEDEHEART Registry. J Am Heart Assoc. 2021 Jan 5;10(1):e017966. doi: 10.1161/JAHA.120.017966. Epub 2020 Nov 30. PMID: 33251914; PMCID: PMC7955471.
  11. Melduni RM, Schaff HV, Bailey KR, Cha SS, Ammash NM, Seward JB, Gersh BJ. Implications of new-onset atrial fibrillation after cardiac surgery on long-term prognosis: a community-based study. Am Heart J. 2015 Oct;170(4):659-68. doi: 10.1016/j.ahj.2015.06.015. Epub 2015 Jun 28. PMID: 26386789.
  12. Ahlsson A, Bodin L, Fengsrud E: Patients with postoperative atrial fibrillation have a doubled cardiovascular mortality. Scand Cardiovasc J. 2009, 43 (5): 330-336. 10.1080/14017430802702291.
  13. Ahlsson, A., Fengsrud, E., Bodin, L. & Englund, A. Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled cardiovascular mortality. Eur. J. Cardiothorac. Surg. 37, 1353–1359 (2010).
  14. Vervoort D, Lee G, Ghandour H, Guetter CR, Adreak N, Till BM, Lin Y. Global Cardiac Surgical Volume and Gaps: Trends, Targets, and Way Forward. Ann Thorac Surg Short Rep. 2023 Dec 9;2(2):320-324. doi: 10.1016/j.atssr.2023.11.019. PMID: 39790140; PMCID: PMC11708342.

Learn More About Investing in BioXgen

Submit your details to access our exclusive investor brief and explore how BioXgen is transforming cardiac recovery.

This is not an offer to invest. All investments are made securely through the DealMaker platform.